Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Intermittent dosing of exemestane is non-inferior to daily dosing
  • News

Intermittent dosing of exemestane is non-inferior to daily dosing

  • 5 April 2023
  • Janet Fricker
Intermittent dosing of exemestane is non-inferior to daily dosing
Total
0
Shares
0
0
0
0
0

Giving the aromatase inhibitor (AI) exemestane 25 mg three times weekly was non-inferior to the standard dosing of 25mg daily among study participants who complied with the schedule.

The international, multicentric study, which was supported by the US National Cancer Institute, and published by Davide Serrano et al. in JAMA Oncology, March 23, found that among treatment-compliant patients the exemestane dose of 25mg given three times weekly was non-inferior to the daily dose, in decreasing serum estradiol.

“These data support the use of a three-times-weekly schedule for further studies of exemestane in breast cancer prevention,” conclude Bernardo Bonanni, from IEO, Milan, and Andrea DeCensi, from Ospedali Galliera, Genova, PI and Co-PI of the study.

The uptake of AIs in both preventive and adjuvant settings havs been hampered by their side effects. Statistics suggest that at least one third of women who start AI therapy stop prematurely due to adverse effects, most frequently musculoskeletal symptoms. An underlying question is whether there is a ‘sweet spot’ of AI dose or frequency that maintains efficacy but minimises adverse effects sufficiently to improve uptake and compliance, and avoid premature discontinuation.

Exemestane is a steroidal aromatase inhibitor whose action results in an irreversible binding to the aromatase enzyme, causing permanent inactivation even when the drug is cleared, suggesting that the agent may have long-term effects.

In the published phase IIb study, the non-inferiority percentage change of serum estradiol using two alternative exemestane schedules (25mg given three times weekly or once weekly) were compared with the standard dose of 25mg daily.

Between February 2017 and August 2019, 171 women with oestrogen receptor-positive early breast cancer who were candidates for surgery were randomly assigned 1:1:1 to receive exemestane at 25mg three times weekly (n=56), once weekly (n=60) or once daily (n=55) for four to six weeks prior to surgery. Blood samples were collected at baseline and the final visit.

Serum estradiol concentrations, measured by solid-phase extraction followed by liquid chromatography-tandem mass spectrometry, was the primary endpoint, since it represents a direct marker of drug potency.

Results showed that, in the intention-to-treat population, the reduction in serum estradiol, by least square mean percentage change, was minus 89% for the once-daily arm, minus 85% for the three-times-weekly arm, and minus 60% for the once-weekly arm. The difference between the once-daily and three-times-weekly arms was 3.6% (P for non-inferiority = 0.37).

For the 153 participants who complied with the schedules, the reduction in serum estradiol was minus 91% for the once-daily, minus 92% for three-times-weekly, and minus 69% for once-weekly arm. The difference between the once-daily and three-times-weekly arms was 2.0% (P for non-inferiority = 0.02).

Regarding secondary endpoints, Ki-67% (used as a measure of cancer cell proliferation) was reduced in all arms, showing median absolute percentage changes of minus 7.5% for once daily, minus 5.0% for three times weekly, and minus 4.0% for once weekly.

Adverse events were similar in all the three arms.

The different findings between compliant and non-compliant participants, suggest the authors, were probably due to the lower variability in estradiol levels among compliant individuals. Regarding the finding that all three dosages showed similar magnitudes of adverse events, the authors suggest that the short treatment duration likely prevented reliable conclusions.

Prior to launching primary prevention and adjuvant trials of three times weekly regimens, the authors suggest that a study of six to 12 months should be investigated to document whether long-term adverse events are reduced among those taking less frequent doses.

In an invited commentary, Carol Fabian and Dinesh Pal Mudaranthakam, from the University of Kansas Medical Center, write, “Taken together, changes in both estrogen levels and Ki-67 suggest further study for the three-times weekly dose but not the once-weekly dose despite the inability to demonstrate noninferiority for estradiol suppression in the ITT [intention to treat] analysis or a reduction in adverse effects in the reduced frequency arms.”

Fabian and Pal Mudaranthakam believe that a reduced frequency approach (involving a three-times-a-week dosing schedule) would prove more attractive to patients than a prolonged holiday approach. “Furthermore, the ability to readily monitor estradiol levels would allow conversion to a daily dose if suppression is not optimal,” they write.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • adjuvant treatment
  • aromatase inhibitors
  • breast cancer prevention
  • estradiol
  • exemestane
  • musculoskeletal symptoms
  • prolonged drug holiday
  • reduced frequency
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Delivery of Care

Unpaid women carers: recognising their contribution and their needs in Latin America

  • 5 April 2023
  • Myriam Vidal Valero
View Post
Next Article
  • Articles
  • Featured

Molecular tumour boards: translating data into tailored therapeutics

  • 6 April 2023
  • Manuela Maria Campanelli
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.